Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : 8VC
Deal Size : $70.0 million
Deal Type : Series B Financing
Tempero Bio Secures $70M Series B to Advance TMP-301 in Phase 2 for SUD
Details : The proceeds will be used to advance TMP-301 through the mid-stage clinical trial studies for alcohol use disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 24, 2025
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : 8VC
Deal Size : $70.0 million
Deal Type : Series B Financing
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMP-301 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2024
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Interaction Between TMP-301 and Cocaine.
Details : TMP-301 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2024
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose Study of TMP-301 in Healthy Subjects
Details : TMP-301 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TMP-301 is a selective mGlurR5 negative allosteric modulator (NAM) designed to reduce excessive glutamate signaling, offering potential as a novel therapeutic in areas of high unmet treatment need in substance use disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2023
Lead Product(s) : TMP-301
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable